Mitoxantrone and Cytarabine Induction, High-Dose Cytarabine, and Etoposide Intensification for Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia: Children’s Cancer Group Study 2951
Authors:
- Robert J. WellsRWRobert J. Wells
- Mary T. AdamsMAMary T. Adams
- Todd A. AlonzoTATodd A. Alonzo
- Robert J. ArceciRARobert J. Arceci
- Jonathan BuckleyJBJonathan Buckley
- Allen B. BuxtonABAllen B. Buxton
- Kathryn DusenberyKDKathryn Dusenbery
- Alan GamisAGAlan Gamis
- Margaret MastersonMMMargaret Masterson
- Terry VikTVTerry Vik
- Phyllis WarkentinPWPhyllis Warkentin
- James A. WhitlockJWJames A. Whitlock
- 1 August 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (15) , 2940-2947
Abstract
Purpose: To evaluate the response rate, survival, and toxicity of mitoxantrone and cytarabine induction, high-dose cytarabine and etoposide intensification, and further consolidation/maintenance therapies, including bone marrow transplantation, in children with relapsed, refractory, or secondary acute myeloid leukemia (AML). To evaluate response to 2-chlorodeoxyadenosine (2-CDA) and etoposide (VP-16) in patients who did not respond to mitoxantrone and cytarabine. Patients and Methods: Patients with relapsed/refractory AML (n = 101) and secondary AML (n = 13) were entered. Results: Mitoxantrone and cytarabine induction achieved a remission rate of 76% for relapsed/refractory patients and 77% for patients with secondary AML, with a 3% induction mortality rate. Cytarabine and etoposide intensification exceeded the acceptable toxic death rate of 10%. The response rate of 2-CDA/VP-16 was 8%. Two-year overall survival was estimated at 24% and was better than historical control data. Patients with secondary AML had similar outcomes to relapsed or refractory patients. Initial remission longer than 1 year was the most important prognostic factor for patients with primary AML (2-year survival rate, 75%), whereas for patients with primary AML, with less than 12 months of initial remission, survival was 13% and was similar to that of refractory patients (6%). Conclusion: Mitoxantrone and cytarabine induction is effective with reasonable toxicity in patients with relapsed/refractory or secondary AML. The cytarabine and etoposide intensification regimen should be abandoned because of toxicity. Patients with relapsed AML with initial remissions longer than 1 year have a relatively good prognosis.Keywords
This publication has 22 references indexed in Scilit:
- A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer GroupBlood, 2001
- Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trialBritish Journal of Haematology, 1998
- A Phase I/II Study of Idarubicin (Ida) with Continuous Infusion Fludarabine (F-ara-A) and Cytarabine (ara-C) for Refractory or Recurrent Pediatric Acute Myeloid Leukemia (AML)Journal of Pediatric Hematology/Oncology, 1997
- Second allogeneic bone marrow transplantation in acute leukemia: a multicenter study from the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)Leukemia, 1997
- High-dose cytosine arabinoside and etoposide: an effective regimen without anthracyclines for refractory childhood acute non-lymphocytic leukemiaLeukemia, 1997
- Autologous Bone Marrow Transplantation versus Intensive Consolidation Chemotherapy for Acute Myeloid Leukemia in ChildhoodNew England Journal of Medicine, 1996
- Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Childrens Cancer Group study.Journal of Clinical Oncology, 1994
- Autologous Bone Marrow Transplantation in Patients with Acute Nonlymphocytic Leukemia, Using ex Vivo Marrow Treatment with 4-HydroperoxycyclophosphamideNew England Journal of Medicine, 1986
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- On a Test of Whether one of Two Random Variables is Stochastically Larger than the OtherThe Annals of Mathematical Statistics, 1947